Roivant Sciences Ltd.’s Immunovant Inc. is bullish about the best-in-class potential of the neonatal fragment crystallizable receptor (FcRn) inhibitor IMVT-1402, leading the company to prioritize the earlier-stage asset ahead of its late-stage FcRn program for batoclimab, which is in Phase III for myasthenia gravis (MG) and thyroid eye disease (TED).
Immunovant Swaps Out Lead Assets
The Roivant-owned company plans to initiate a broad clinical trial program for IMVT-1402 in multiple indications, prioritizing it over batoclimab, which remains in Phase III development.
